Skip to main content

Table 1 Association between EmiR expression at Ext1 and clinicopathological characteristics in LBC patients

From: Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy

   Ext1
EmiR-21 EmiR-222 EmiR-221 EmiR-105 EmiR-155
n Median p value Median p value Median p value Median p value Median p value
Age (years) < 50 27 1.518 0.983 1.506 0.966 1.161 0.667 11.199 0.897 1.901 0.302
≥ 50 20 1.671 1.592 1.375 8.362 3.247
Menopause Pre 30 1.579 0.330 1.585 0.658 1.399 0.232 9.474 0.947 1.904 0.250
Post 17 1.424 1.424 1.088 8.597 3.370
T T1–T2 27 1.265 0.039* 1.506 0.813 1.173 0.780 3.851 0.067 1.906 0.093
T3–T4 20 1.787 1.556 1.379 22.184 4.073
N 0 20 1.443 1.000 1.315 0.342 1.197 0.733 8.362 0.846 2.436 0.770
1–3 23 1.543 1.584 1.088 30.239 3.019
Estrogen receptor Negative 13 1.615 0.812 2.992 0.161 1.221 0.812 49.757 0.140 2.776 0.981
Positive 34 1.462 1.417 1.155 7.072 2.892
Progesterone receptor Negative 17 1.615 0.773 2.992 0.018* 1.597 0.465 49.757 0.116 2.776 0.947
Positive 30 1.403 1.271 1.064 7.072 2.778
HER2 Negative 36 1.531 0.466 1.465 0.880 1.149 0.563 8.362 0.744 3.117 0.421
Positive 11 1.265 2.019 1.596 14.130 1.055
KI67 < 20% 8 1.157 0.458 0.850 0.050 1.279 0.573 3.380 0.103 2.219 0.373
≥ 20 37 1.518 1.584 1.161 14.130 3.019
Perou’s classification Basal-like 8 1.566 0.976 3.179 0.037* 1.191 0.986 39.998 0.306 4.127 0.495
Luminal A 7 1.543 0.803 1.656 3.389 1.901
Luminal B 27 1.424 1.513 1.139 7.750 3.215
HER2neu 5 1.960 2.094 1.597 60.097 1.055
  1. Wilcoxon signed-rank test and Kruskal-Wallis test were used. Abbreviations: CTCs circulating tumor cells, Ext1 basal extraction, Ext2 extraction during neoadjuvant treatment, T tumor size, N lymph node status. *p > 0.05